Holen Sie sich die Stockscreener-App
19.14
5.22%
0.95
Handel nachbörslich:
19.16
0.02
+0.10%
Bioage Labs Inc Aktie (BIOA) Neueste Nachrichten
BTIG Initiates BioAge Labs(BIOA.US) With Buy Rating, Announces Target Price $40 - Moomoo
BioAge Labs, Inc (BIOA) Stock News & Articles - 24/7 Wall St.
Earnings Update: Here's Why Analysts Just Lifted Their BioAge Labs, Inc. (NASDAQ:BIOA) Price Target To US$53.33 - Yahoo Finance
BTIG Initiates BioAge Labs at Buy With $40 Price Target - marketscreener.com
Analysts Offer Insights on Healthcare Companies: BioAge Labs, Inc. (BIOA) and Lexeo Therapeutics, Inc. (LXEO) - The Globe and Mail
Earnings Beat: BioAge Labs, Inc. (NASDAQ:BIOA) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts - simplywall.st
TradingKey - TradingKey
BioAge Labs: Analyst Reiterates Buy on Best-in-Class Potential of Lead NLRP3 Inhibitor BGE-102 After Encouraging Phase 1/2 Data - TipRanks
BioAge Labs Releases Q1 2026 Financial Results - AlphaStreet
BioAge Labs, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
BioAge Labs 1Q Loss/Shr 52c >BIOA - Moomoo
BioAge Labs Q1 Loss Widens, Collaboration Revenue Rises - marketscreener.com
BioAge Labs Reports Positive Phase 1 Results for BGE-102 and Plans Upcoming Clinical Trials in Cardiovascular Risk and Diabetic Macular Edema - Quiver Quantitative
Earnings Flash (BIOA) BioAge Labs, Inc. Reports Q1 Collaboration Revenue $2.8M, vs. FactSet Est of $1.1M - marketscreener.com
BioAge Labs (NASDAQ: BIOA) Q1 2026 loss deepens amid R&D and pipeline push - Stock Titan
[10-Q] BioAge Labs, Inc. Quarterly Earnings Report - Stock Titan
BioAge lines up 2 mid-2026 trials for once-daily pill after $132M raise - Stock Titan
Earnings Flash (BIOA) BioAge Labs, Inc. Reports Q1 Collaboration Revenue $2.8M, Vs. FactSet Est of $1.1M - Moomoo
Press Release: BioAge Labs Reports First Quarter 2026 Financial Results and Provides Business Updates - Moomoo
BioAge to preview early data for heart and retinal disease drug - Stock Titan
BioAge to Host R&D Day Focused on NLRP3 Inhibition on May 8, 2026 - The Manila Times
BlackRock (NYSE: BIOA) reports 2.24M shares of BioAge; 5.03% stake - Stock Titan
BioAge Labs (NASDAQ:BIOA) Trading 8.6% HigherHere's Why - MarketBeat
BioAge Labs plans up to $75M public stock offering; shares down - MSN
Wall Street Zen Downgrades BioAge Labs (NASDAQ:BIOA) to Sell - MarketBeat
BioAge Labs (BIOA) CFO exercises 3,542 options, now holds 36,575 shares - Stock Titan
BioAge Labs Touts Phase 1 BGE-102 Data, Citing 86% hs-CRP Drop and Clean Safety Profile - MarketBeat
BIOA FINAL DEADLINE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages BioAge Labs, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important March 10 Deadline in Securities Class ActionBIOA - TMX Newsfile
BIOA SEC FilingsBioAge Labs Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
BioAge Labs (NASDAQ:BIOA) Stock Price Down 6.1%Time to Sell? - MarketBeat
BioAge Labs Stock Gains After Positive Early Data And Pipeline Plans - Sahm
BIOA (BioAge Labs Inc.) Q4 2025 loss narrows more than expected, shares climb 8.83 percent on investor enthusiasm.Management Guidance - Xã Vĩnh Công
[ARS] BioAge Labs, Inc. SEC Filing - Stock Titan
Jefferies reiterates BioAge Labs stock rating on dose data By Investing.com - Investing.com South Africa
Directors and auditor up for approval at BioAge Labs (NASDAQ: BIOA) 2026 meeting - Stock Titan
Jefferies reiterates BioAge Labs stock rating on dose data - Investing.com
BioAge Labs (BIOA): Phase 1 BGE-102 Data Reinforce Best-in-Class NLRP3 Potential and De-Risk 2026 Cardiovascular Phase 2, Supporting Buy Rating - TipRanks
BioAge says early data suggest ‘best-in-class’ potential for inflammation drug - BioPharma Dive
BioAge Reports Positive Phase 1 Data for BGE-102 - Lifespan Research Institute
Wall Street Analysts Predict an 183.67% Upside in BioAge Labs, Inc. (BIOA): Here's What You Should Know - Yahoo Finance
BioAge's BGE-102 Shows Deep Reductions In Inflammation Markers In Phase 1 Trial, Stock Up - RTTNews
BioAge reports Phase 1 results for NLRP3 inhibitor BGE-102 - Investing.com
BioAge reports Phase 1 results for NLRP3 inhibitor BGE-102 By Investing.com - Investing.com Canada
BGE-102 60 mg once daily achieves equivalent hsCRP reduction as 120 mg, BioAge Labs, Inc. finds - Traders Union
BioAge Reports Positive Phase 1 Data for BGE-102, a Novel - GlobeNewswire
BioAge Labs (BIOA) Stock: Should You Take Exposure (Volatility Increases) 2026-04-20Earnings Beat Stocks - Xã Thanh Hà
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of March 10, 2025 in BioAge Labs, Inc. LawsuitBIOA - ACCESS Newswire
BioAge Labs (NASDAQ:BIOA) Shares Up 10.3%Still a Buy? - MarketBeat
Needham Maintains BioAge Labs(BIOA.US) With Buy Rating, Maintains Target Price $50 - 富途牛牛
BioAge Labs Highlights BGE-102 Catalysts, DME Study Plans and $285M Cash at Needham Conference - MarketBeat
BioAge LabsOral NLRP3 Inhibitor Could Establish PoC In CV This Year (NASDAQ:BIOA) - Seeking Alpha
BioAge Labs (BIOA) price target increased by 44.67% to 44.27 - MSN
BioAge Labs to Present at 25th Annual Needham Virtual Healthcare Conference - The Manila Times
BioAge CEO's April 16 fireside chat will stream live online - Stock Titan
4.17%
0.58%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):